Trial Profile
A Randomised, Double-blind, Placebo-controlled, Cross-over Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of GSK2239633 in Healthy Male Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Dec 2023
Price :
$35
*
At a glance
- Drugs GSK 2239633 (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 26 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jun 2011 New trial record